Wednesday, October 29, 2025
- 12:00PM-12:15PM
-
Abstract Number: 2665
Preexisting Antibodies Against Vaccine Antigens Are Preserved In Patients With Systemic Lupus Erythematosus and Sjögren’s Disease Upon Ianalumab Treatment While Autoantibodies Decline
Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III: End Organ Focus on Heart, Lung and Eye (2663–2668)- 12:00PM-12:15PM
-
Abstract Number: 2677
Quantified Imaging Response at the Sacroiliac Joints to TNF-Inhibitor Therapy in Youth with Axial Disease
Abstracts: Pediatric Rheumatology – Clinical III (2675–2680)- 12:00PM-12:15PM
-
Abstract Number: 2659
Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Systemic Autoimmune Rheumatic Diseases in Patients with Type 2 Diabetes: A Population-Based Target Trial Emulation
Abstracts: Epidemiology & Public Health I (2657–2662)- 12:15PM-12:30PM
-
Abstract Number: 2696
Biomarker Data From an Open-Label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory SLE
Abstracts: Systemic Lupus Erythematosus – Treatment II (2693–2698)- 12:15PM-12:30PM
-
Abstract Number: 2702
Diagnostic Performance of Vascular Ultrasound in Giant Cell Arteritis – A Single Center Experience
Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II (2699–2704)- 12:15PM-12:30PM
-
Abstract Number: 2690
Dietary interventions in Psoriatic Arthritis: A Randomized controlled clinical trial
Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: Pathogenesis, Exercise, and Dietary Interventions (2687–2692)- 12:15PM-12:30PM
-
Abstract Number: 2684
Multimodal Analysis Revealed Altered Brain Connectivity Patterns and Neuroinflammatory Processes in the Background of Difficult-To-Treat Rheumatoid Arthritis
Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes III: Long Live (Comorbidity and Outcomes) (2681–2686)- 12:15PM-12:30PM
-
Abstract Number: 2666
Rare TNFAIP3 Hypomorphic Variants are a Massively Underestimated Driver of Human Autoinflammatory Disease
Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III: End Organ Focus on Heart, Lung and Eye (2663–2668)- 12:15PM-12:30PM
-
Abstract Number: 2672
Safety and efficacy of Upadacitinib in melanoma differentiation-associated gene 5-positive dermatomyositis with interstitial lung disease: a single-centre, retrospective, propensity score-matched cohort study
Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I: Diagnostics & Therapeutics (2669–2674)- 12:15PM-12:30PM
-
Abstract Number: 2678
The Association Between Medication Taper Duration and Time to JIA Disease Flare: A Retrospective Cohort Study
Abstracts: Pediatric Rheumatology – Clinical III (2675–2680)- 12:15PM-12:30PM
-
Abstract Number: 2660
Understanding Gout in Women: Longitudinal Changes in Serum Urate Levels from Pre-menopause through Post-menopause
Abstracts: Epidemiology & Public Health I (2657–2662)- 12:30PM-12:45PM
-
Abstract Number: 2697
A Prospective Randomized Controlled 96-week Study to Evaluate the Efficacy and Safety of Tacrolimus and Glucocorticoid as Continuous Induction-Maintenance Treatment for Class III/IV±V Lupus Nephritis
Abstracts: Systemic Lupus Erythematosus – Treatment II (2693–2698)- 12:30PM-12:45PM
-
Abstract Number: 2667
Amyloidosis Secondary to Familial Mediterranean Fever: Machine Learning Based Prediction Models
Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III: End Organ Focus on Heart, Lung and Eye (2663–2668)- 12:30PM-12:45PM
-
Abstract Number: 2685
Assessing for Racial/Ethnic Variability in U.S.-FRAXTM Performance Among Older Adult Women with Rheumatoid Arthritis in the United States
Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes III: Long Live (Comorbidity and Outcomes) (2681–2686)- 12:30PM-12:45PM
-
Abstract Number: 2679
Early-Life Nutrition and Gene-Environment Interactions Influencing Juvenile Idiopathic Arthritis Risk: Results from a Pregnancy Cohort